Two-Year Outcome of an Observe-And-Plan Regimen for Neovascular Age-Related Macular Degeneration: How to Alleviate the Clinical Burden With Maintained Functional Results

Eye - United Kingdom
doi 10.1038/eye.2014.321
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Functional and Anatomical Outcome of Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab Following an Exit Strategy Regimen

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2014English

Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

Scientific Reports
Multidisciplinary
2019English

Aflibercept for Neovascular Age-Related Macular Degeneration

Cochrane Database of Systematic Reviews
2016English

Treat-And-Extend Versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

Ophthalmology
Ophthalmology
2018English

Macular Atrophy in Neovascular Age Related Macular Degeneration

Journal of Clinical Review & Case Reports
2019English

An Evaluation of Photographic Screening for Neovascular Age-Related Macular Degeneration

Eye
MedicineArtsSensory SystemsOphthalmologyHumanities
2005English

Macular Functional Changes in Patients With Neovascular Age-Related Macular Degeneration Receiving Ranibizumab Therapy (Lucentis)

BMC Geriatrics
GerontologyGeriatrics
2010English

Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine
Medicine
2006English

Aflibercept Improves Outcome in Eyes With Poor Vision From Neovascular Age-Related Macular Degeneration

Acta Ophthalmologica
MedicineOphthalmology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy